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Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited
small vessel disease characterised by recurrent ischemic stroke, cognitive decline progressing to dementia, psychiatric
disturbances and apathy. More than half of mutation carriers suffer from migraine, most often migraine with aura.
Recently, a CADASIL patient was treated with a monoclonal antibody targeting the calcitonin gene-related peptide
(CGRP) receptor. Monoclonal antibodies targeting the CGRP system have been demonstrated to be safe, well tolerated,
and effective in reducing migraine attacks. There is, however, abundant evidence that CGRP is important in maintaining
cardiovascular homeostasis under (patho)physiological conditions. CGRP may act as a vasodilatory safeguard during
cerebral and cardiac ischemia and blockage of the system could, therefore, potentially worsen ischemic events.
Therefore, we caution against treating patients with small vessel diseases, such as the monogenic disorder CADASIL,
with these drugs until relevant safety data and long term follow up results are available. Alternative preventive migraine
treatments in CADASIL may be acetazolamide, sodium valproate, lamotrigine, topiramate, verapamil, or flunarizine.
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Until recently, migraine management remained rela-
tively unsatisfactory and without mechanistic rationale.
Compounds have been developed to either inactivate
the calcitonin gene-related peptide (CGRP) molecule
by binding to it or its receptor, to prevent migraine
from developing. These monoclonal antibodies against
CGRP or its receptor are safe, well tolerated, and effec-
tive in reducing migraine attacks and headache days.
Cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy
(CADASIL) is an inherited small vessel disease.
CADASIL is characterised by mid-adult onset of
recurrent ischemic stroke, cognitive decline progressing
to dementia, psychiatric disturbances and apathy, with
diffuse white matter lesions and subcortical infarcts on
neuroimaging. More than half of mutation carriers
suffer from migraine, most often migraine with aura
(1). Migraine is the inaugural manifestation in 40% of
patients. Atypical aura symptoms occur in two thirds of
mutation carriers who experience migraine (1).
Recently, a middle-aged CADASIL patient was
treated with CGRP-receptor monoclonal antibody ere-
numab for chronic migraine (2). This patient suffered
from frequent migraine attacks with atypical auras
consisting of visual and confusional symptomatology.
The authors reported a favourable response and sug-
gested that this may be a safe treatment for CADASIL
patients.
CGRP and its receptor are abundantly present in
the vasculature and maintain cardiovascular
1Department of Neurology, Leiden University Medical Center, Leiden,
the Netherlands
2Division of Pharmacology and Vascular Medicine, Department of
Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
Corresponding author:
Gisela Terwindt, Department of Neurology, Leiden University Medical









homeostasis under (patho)physiological conditions.
CGRP may act as a vasodilatory safeguard during
cerebral and cardiac ischemia and blockage of the
system might, therefore, potentially worsen ischemic
events. Although CGRP monoclonal antibodies seem
safe, three deaths were reported in clinical migraine
trials (3). During treatment with fremanezumab, two
patients died (suicide and chronic obstructive pulmo-
nary disease) (3). One patient treated with erenumab
died due to an ‘arteriosclerosis event’ (3). Patients
included in these trials were likely considered ‘healthy’
besides having migraine. In regular clinical practice, a
41-year old woman suffered an ischemic stroke after
erenumab was started, no vascular risk factors besides
combined oral contraceptive use were present (4).
For patients with increased stroke risk, including
those with a monogenetic predisposition such as
CADASIL, reports of ischemic events are especially
troubling. It should be taken into account that
CADASIL is a small vessel disease, and aberrant
CGRP-mediated microvascular responses have been
demonstrated in CADASIL patients (5). Blockade of
the CGRP-ergic system may further increase cardiovas-
cular risk in this patient group. Furthermore, the
reported suicide is concerning as CADASIL patients
are already predisposed to psychiatric illnesses.
Lastly, long-term effects of CGRP blockade are still
unknown.
Treatment of migraine in CADASIL is based on
empirical data and personal experience. Moreover,
treatment needs to take into account risk for ischemic
events and psychiatric illness. From personal
experience, preventive treatment focusing on (atypical)
aura is most effective, including acetazolamide, sodium
valproate, lamotrigine, topiramate, verapamil, or flu-
narizine. Depending on other headache comorbidity
(migraine without aura, daily “tension-type-like” head-
ache), candesartan or amitriptyline may be effective.
Due to the rarity of CADASIL, it is highly unlikely
that enough patients can be recruited to perform clin-
ical trials on efficacy and/or complications of CGRP-
(receptor) antibodies. As an example, whether
CADASIL patients should be treated with antiplatelet
medication (a frequently debated subject with great rel-
evance) still remains based on expert opinions.
Nevertheless, fundamental research can provide addi-
tional information about the effect of blocking the
CGRPergic system in this disorder. Recent work in
healthy mice already demonstrated that blocking the
CGRP system leads to worsened experimental ischemic
stroke by inhibiting CGRP-mediated collateral vasodi-
lation (6). While this may be regarded already as a
warning signal that these treatments should not be pre-
scribed to CADASIL patients, work in genetically
modified CADASIL mice models will provide addi-
tional information about possible risks.
In CADASIL, ischemic events frequently occur, and
their outcome could be worsened by blocking the
CGRP system. Therefore, blocking CGRP may pose
a risk in patients with small vessel diseases such as
CADASIL and we strongly advise refraining from
CGRP-blocking treatments until their long-term
safety is proven.
Clinical implications
• In CADASIL, cerebral ischemic events frequently occur, and their outcome may be worsened by blocking
the CGRP system.
• We strongly advise refraining from CGRP-blocking treatments in patients with small vessel diseases such
as CADASIL until long-term safety is proven in case of ischemic events.
• Based on personal experience, specific preventive treatment for (a)typical migraine with aura is effective in
CADASIL patients, including acetazolamide, sodium valproate, lamotrigine, topiramate, verapamil, or
flunarizine.
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